SUTRO BIOPHARMA, INC. Revenues
SUTRO BIOPHARMA, INC. (STRO) reported Revenues of $11.30 million for the 3-month period ending 2019-12-31, per its 10-K filed 2020-03-16.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2020-03-16
- SUTRO BIOPHARMA, INC. revenues for the quarter ending 2019-12-31 was $11.30M, a 40.77% decline year-over-year.
- SUTRO BIOPHARMA, INC. revenues for the quarter ending 2019-09-30 was $12.28M, a 56.67% increase year-over-year.
- SUTRO BIOPHARMA, INC. revenues for the quarter ending 2019-06-30 was $10.53M, a 84.52% increase year-over-year.
- SUTRO BIOPHARMA, INC. revenues for the quarter ending 2019-03-31 was $8.63M, a 48.96% increase year-over-year.
- SUTRO BIOPHARMA, INC. revenues for fiscal 2018 was $38.42M, a 25.75% decline from fiscal 2017.
- SUTRO BIOPHARMA, INC. revenues for fiscal 2017 was $51.74M, a 13.38% decline from fiscal 2016.
- SUTRO BIOPHARMA, INC. revenues for fiscal 2016 was $59.73M.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2019-12-31 | $11.30M 10-K · filed 2020-03-16 | $23.58M derived: sum of 2 quarters · filed 2020-03-16 | $34.11M derived: sum of 3 quarters · filed 2020-03-16 | $42.74M derived: sum of 4 quarters · filed 2020-03-16 |
| 2019-09-30 | $12.28M 10-K · filed 2020-03-16 | $22.80M derived: sum of 2 quarters · filed 2020-03-16 | $31.43M derived: sum of 3 quarters · filed 2020-03-16 | $50.52M derived: sum of 4 quarters · filed 2020-03-16 |
| 2019-06-30 | $10.53M 10-K · filed 2020-03-16 | $19.15M derived: sum of 2 quarters · filed 2020-03-16 | $38.24M derived: sum of 3 quarters · filed 2020-03-16 | $46.08M derived: sum of 4 quarters · filed 2020-03-16 |
| 2019-03-31 | $8.63M 10-K · filed 2020-03-16 | $27.71M derived: sum of 2 quarters · filed 2020-03-16 | $35.55M derived: sum of 3 quarters · filed 2020-03-16 | $41.26M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-12-31 | $19.09M 10-K · filed 2020-03-16 | $26.92M derived: sum of 2 quarters · filed 2020-03-16 | $32.63M derived: sum of 3 quarters · filed 2020-03-16 | $38.42M 10-K · filed 2019-04-01 |
| 2018-09-30 | $7.84M 10-K · filed 2020-03-16 | $13.54M derived: sum of 2 quarters · filed 2020-03-16 | $19.33M 10-Q · filed 2018-11-14 | $23.37M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | $5.70M 10-K · filed 2020-03-16 | $11.50M derived: sum of 2 quarters · filed 2020-03-16 | $15.54M derived: sum of 3 quarters · filed 2020-03-16 | $33.04M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-03-31 | $5.79M 10-K · filed 2020-03-16 | $9.83M derived: sum of 2 quarters · filed 2020-03-16 | $27.33M derived: sum of 3 quarters · filed 2020-03-16 | $42.69M derived: sum of 4 quarters · filed 2020-03-16 |
| 2017-12-31 | $4.04M 10-K · filed 2019-04-01 | $21.54M derived: sum of 2 quarters · filed 2019-04-01 | $36.90M derived: sum of 3 quarters · filed 2019-04-01 | $51.74M 10-K · filed 2019-04-01 |
| 2017-09-30 | $17.50M 10-K · filed 2019-04-01 | $32.86M derived: sum of 2 quarters · filed 2019-04-01 | $47.70M 10-Q · filed 2018-11-14 | |
| 2017-06-30 | $15.36M 10-K · filed 2019-04-01 | $30.20M derived: sum of 2 quarters · filed 2019-04-01 | ||
| 2017-03-31 | $14.85M 10-K · filed 2019-04-01 | |||
| 2016-12-31 | $59.73M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |